News
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
2d
Stocktwits on MSNRegeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D EffortsDrugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results